Key result
Racemic ibuprofen dose-dependently increased the maximum percentage inhibition of TXB2 generation, from 93.4% after a 200 mg dose to 98.8% after a 1200 mg dose.
Why the study?
Does increasing the dose of racemic ibuprofen improve the magnitude and duration of platelet cyclo-oxygenase inhibition in healthy male subjects?
RCT (n=4)
Latin-square
Does increasing the dose of racemic ibuprofen improve the magnitude and duration of platelet cyclo-oxygenase inhibition in healthy male subjects?
Absolute Event Rate: 98.8% vs 93.4%
Increasing doses of racemic ibuprofen up to 1200 mg transiently and dose-dependently inhibit platelet thromboxane generation, mirroring the plasma concentration of unbound S(+)-ibuprofen.
No takes yet. Share an insight, caveat, or question.
Higher ibuprofen doses may enhance in vitro platelet TXB2 inhibition; leaves open clinical translation and antiplatelet utility in patients.
Am et al. (1991) conducted an RCT in Healthy (n=4). Racemic ibuprofen vs. Different doses was evaluated on Maximum percentage inhibition of TXB2 generation. Racemic ibuprofen dose-dependently increased the maximum percentage inhibition of TXB2 generation, from 93.4% after a 200 mg dose to 98.8% after a 1200 mg dose.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: